ライフサイエンスコーパス: vaginal mucosa

1 innate and adaptive immune responses in the vaginal mucosa.

2 penetrating epithelial barriers such as the vaginal mucosa.

3 strategy for immune protection of rectal and vaginal mucosa.

4 antibodies and T cells were observed in the vaginal mucosa.

5 duced CD8(+) T-cell responses in the gut and vaginal mucosa.

6 effective delivery vehicles for siRNA to the vaginal mucosa.

7 h rate of HIV infection in women through the vaginal mucosa.

8 viral replication and spread throughout the vaginal mucosa.

9 he heterosexual transmission of HIV-1 at the vaginal mucosa.

10 ecific CD8 T cells in tissues, including the vaginal mucosa.

11 the mechanism of immune induction within the vaginal mucosa.

12 rding the phenotype of CD4(+) T cells in the vaginal mucosa.

13 to DC-SIGN(+) cells is limited in an intact vaginal mucosa.

14 defense mechanism against C. albicans at the vaginal mucosa.

15 ortant component in immune protection of the vaginal mucosa.

16 that affect immunity after challenge at the vaginal mucosa.

17 effector function from the periphery to the vaginal mucosa.

18 ent memory CD8 T cells in the intestinal and vaginal mucosa.

19 the genital tract draining nodes and in the vaginal mucosa; 2) had significantly lower virus titers;

20 common commensal of the gastrointestinal and vaginal mucosa and a leading cause of serious infections

21 er numbers of Ag-specific CD8 T cells in the vaginal mucosa and iliac lymph node, as well as 2-3x mor

22 ocal CD8(+) T cell-mediated responses in the vaginal mucosa and ILNs, the mice were protected against

23 ated responses were detected locally, in the vaginal mucosa and in the draining iliac lymph nodes (IL

24 a clade C FIV isolate via the oral-nasal or vaginal mucosa and multiple tissues were examined by vir

25 n the design of vaccines to protect both the vaginal mucosa and sensory ganglia against HSV-2.

26 ine endometrium, endocervix, ectocervix, and vaginal mucosa) and temporally throughout the menstrual

27 at each interval consisted of vaginal wall, vaginal mucosa, and clitoris assessments; femoral vein s

28 aginal tract, and T cell responses in blood, vaginal mucosa, and draining lymph nodes that rapidly ex

29 tective Th1 immune responses to HSV-2 in the vaginal mucosa, and suggest their importance in immunity

30 viruses, transported them through explanted vaginal mucosa, and transmitted them in trans to vaginal

31 howed that 45% +/- 10% of lymphocytes in the vaginal mucosa are CD3+ compared with 75% +/- 5% in LNC

32 The gastrointestinal and vaginal mucosa are the major routes of natural HIV trans

33 d in the penetration of superantigens across vaginal mucosa as a representative nonkeratinized strati

34 FIV RNA was detected in tonsil and oral or vaginal mucosa as early as 1 day p.i. by TSA-ISH and in

35 ed R5 HIV-1 entered macrophages in explanted vaginal mucosa as early as 30 min after inoculation of v

36 We show that a low number of pDCs survey the vaginal mucosa at steady state.

37 s via heterosexual contact, with the cervico-vaginal mucosa being the main portal of entry in women.

38 ice resulted in diminished protection of the vaginal mucosa, but not of the sensory ganglia.

39 The vaginal mucosa can be colonized by many bacteria includi

40 e function of Ag-specific CD8 T cells in the vaginal mucosa comparing the two routes of infection.

41 albicans infection in mice is limited at the vaginal mucosa despite a strong Candida-specific Th1-typ

42 unced diminution of virus clearance from the vaginal mucosa despite the presence of HSV-specific B an

43 s and chemokines are present at the oral and vaginal mucosa during C. albicans infections.

44 significant increases in numbers within the vaginal mucosa during infection.

45 decreased challenge virus replication in the vaginal mucosa, genital and neurological disease, and mo

46 nic exotoxin A, respectively, across porcine vaginal mucosa in an ex vivo model of superantigen penet

47 l receptor, which allows it to penetrate the vaginal mucosa, induce interleukin-8, and cause toxic sh

48 the mouse vagina were transported across the vaginal mucosa into draining lymph nodes, but not into d

49 The cervico-vaginal mucosa is naturally colonized with commensal bac

50 or type 1 pili on the squamous epithelium of vaginal mucosa is unknown.

51 to SAg profiles of skin lesion isolates and vaginal mucosa isolates revealed that the SAg profile of

52 show that the lack of APC maturation in the vaginal mucosa leads to a delay in CD8 T cell activation

53 ntigen exotoxins absorbed through the gut or vaginal mucosa, little is known regarding the pathogenes

54 ced epithelial cell membrane blebbing in the vaginal mucosa may play a role in the pathogenesis of BV

55 meability model, mutant D130A penetrated the vaginal mucosa more quickly than wild type toxin.

56 llenge, of antiviral effector T cells in the vaginal mucosa of female rhesus macaques immunized with

57 of patients with atopic dermatitis and from vaginal mucosa of healthy individuals.

58 In the vaginal mucosa of imiquimod-treated monkeys, we document

59 l persistence, showed that GBS colonized the vaginal mucosa of mice at high numbers (10(6)-10(7) CFU/

60 producible, asymptomatic colonization of the vaginal mucosa over a period of typically 3 to 4 weeks'

61 influx of lymphocytes, may cause changes in vaginal mucosa permeability, facilitating TSST-1 penetra

62 cherichia coli to carbohydrate structures of vaginal mucosa plays a major role in the pathogenesis of

63 ement of innate-mediated inflammation in the vaginal mucosa rescues this phenotype and completely inh

64 We provide evidence that the vaginal mucosa supports both the local immune priming of

65 timely appearance of effector CD8 T cells in vaginal mucosa, thus further delaying viral control in t

66 thogenic and poorly transmissible across the vaginal mucosa to a variant that still maintains CCR5 us

67 he superantigen must therefore penetrate the vaginal mucosa to interact with underlying immune cells

68 The vaginal mucosa undergoes cyclic changes under the contro

69 of a cytomegalovirus promoter (pCMV/HGH) via vaginal mucosa (V), Peyer's patch (PP), and/or abdominal

70 Viral entry through the vaginal mucosa was also inhibited by preincubation of HS

71 he human fallopian tube, uterus, cervix, and vaginal mucosa were examined for susceptibility to infec

72 At necropsy, lymphoid tissues and vaginal mucosa were virus culture negative, but in 10 of

73 s in the systemic compartment but not in the vaginal mucosa, while the same antibodies injected intra

74 hese findings indicate that targeting of the vaginal mucosa with a Lipo/rAdv5 prime/boost vaccine eli

75 nd CD8(+) T-cell responses in the rectal and vaginal mucosa with greater functional heterogeneity tha

76 we show that these viruses replicate in the vaginal mucosa with minimal induction of antiviral inter

77 ear leukocytes (PMNs) infiltrated the murine vaginal mucosa within 24 h after intravaginal inoculatio

78 We now show that SIV enters the vaginal mucosa within 60 min of intravaginal exposure, i